TY - JOUR
T1 - Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies
AU - Kardassis, Dimitris
AU - Vindis, Cécile
AU - Stancu, Camelia Sorina
AU - Toma, Laura
AU - Gafencu, Anca Violeta
AU - Georgescu, Adriana
AU - Alexandru-Moise, Nicoleta
AU - Molica, Filippo
AU - Kwak, Brenda R.
AU - Burlacu, Alexandrina
AU - Hall, Ignacio Fernando
AU - Butoi, Elena
AU - Magni, Paolo
AU - Wu, Junxi
AU - Novella, Susana
AU - Gamon, Luke F.
AU - Davies, Michael J.
AU - Caporali, Andrea
AU - de la Cuesta, Fernando
AU - Mitić, Tijana
N1 - Publisher Copyright:
© 2024
PY - 2025
Y1 - 2025
N2 - Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.
AB - Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.
KW - Atherosclerosis
KW - Omics technologies
KW - Shear stress and circumferential stretch models
KW - Three-dimensional (3D) models
KW - Two dimensional (2D) models
U2 - 10.1016/j.vph.2024.107452
DO - 10.1016/j.vph.2024.107452
M3 - Review
C2 - 39667548
AN - SCOPUS:85212400520
VL - 158
JO - Vascular Pharmacology
JF - Vascular Pharmacology
SN - 1537-1891
M1 - 107452
ER -